Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Picenadol.

D M Zimmerman, S E Smits, M D Hynes

    Drug and Alcohol Dependence
    |February 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.

    Behavioural pharmacology·2002
    Same author

    In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

    Circulation·2001
    Same author

    Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

    Journal of medicinal chemistry·2001
    Same author

    [3H]N-2-(4-(N-benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand.

    Journal of medicinal chemistry·2001
    Same author

    Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.

    Neuropharmacology·2001
    Same author

    Expression, purification, and characterization of active recombinant prostate-specific antigen in Pichia pastoris (yeast).

    The Prostate·2001
    Same journal

    Mental and somatic multimorbidity among individuals with alcohol use disorder: A sex-stratified registry study.

    Drug and alcohol dependence·2026
    Same journal

    Monitoring novel psychoactive substance trends on social media: Analysis of discussions and dashboard implementation.

    Drug and alcohol dependence·2026
    Same journal

    A meta-analysis on the relationship between cultural identity and substance use among indigenous youth.

    Drug and alcohol dependence·2026
    Same journal

    Examining heterogeneity in pathways between alcohol-related factors and drinking during topiramate pharmacotherapy: A person-specific analysis.

    Drug and alcohol dependence·2026
    Same journal

    The impact of severe mental illness on treatment retention and all-cause mortality among people in opioid agonist treatment.

    Drug and alcohol dependence·2026
    Same journal

    Does treatment status matter? An examination of daily approach and avoidance inclinations predicting drinking in individuals diagnosed with alcohol use disorder.

    Drug and alcohol dependence·2026
    See all related articles

    Picenadol, a novel mixed agonist-antagonist analgesic, demonstrates significant pain relief comparable to morphine with reduced side effects. Its unique d- and l-isomer structure offers potent agonist and antagonist properties, respectively, for improved pain management.

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry
    • Pain Management

    Background:

    • Picenadol is a novel mixed opioid agonist-antagonist analgesic.
    • It is a 4-phenylpiperidine derivative and a racemic mixture.

    Purpose of the Study:

    • To evaluate the analgesic properties and receptor binding profile of picenadol.
    • To assess its potential for side effects and abuse liability.

    Main Methods:

    • Mouse writhing and rat tail heat tests were used to determine analgesic potency.
    • Opioid receptor binding assays were performed.
    • Pharmacological investigations assessed side effect profiles.

    Main Results:

    • Picenadol exhibits analgesic potency approximately 1/3 that of morphine.

    Related Experiment Videos

  • The d-isomer acts as a potent agonist, while the l-isomer is an antagonist.
  • Picenadol shows high affinity for mu and delta opioid receptors, with low affinity for kappa receptors.
  • Low potential for opiate-like side effects, abuse, and physical dependence was observed.

    • Conclusions:

    • Picenadol is a promising analgesic with a favorable therapeutic profile.
    • Its unique isomer-specific activity and receptor binding suggest potential for effective pain management with reduced risks.